There is no measured KLOW peptide before and after. Four compounds share the vial, no study has given them together, and two of the four have never been given to a person in a published trial.
The short answer. No result has been measured for KLOW. Studies of the four-compound combination number zero in any species.
- TB-500 and KPV have no published human trial, so half the vial contributes nothing to any before-and-after.
- The BPC-157 number everyone quotes is a phone survey: 16 knee patients reached, 14 reporting relief, no controls.
- Skin photos borrow GHK-Cu's topical evidence for an injected vial. Injected GHK-Cu has no randomized trial.
KLOW is 80 mg of four compounds: GHK-Cu, BPC-157, TB-500 and KPV. Studies of the combination number zero. The nearest human data belongs to BPC-157, and it is a phone survey of 16 knee patients. TB-500 and KPV have no published human trial of any kind. GHK-Cu’s controlled evidence is topical.
What has been measured, ingredient by ingredient
There is no result for KLOW, so the honest version of this page is a per-ingredient audit. Here is every human number that exists in the vial.
| Component | mg | Human result on record |
|---|---|---|
| GHK-Cu | 50 mg | Controlled dermal studies, topical application only |
| BPC-157 | 10 mg | A phone survey of 16 knee patients, uncontrolled |
| TB-500 | 10 mg | None published |
| KPV | 10 mg | None published |
Read down the third column. Two rows are empty, one is a route this vial does not use, and one is a phone survey. That is the evidence base a KLOW photograph is standing on:
- GHK-Cu — real controlled evidence, generated by rubbing it on skin rather than injecting it.
- BPC-157 — one uncontrolled retrospective review, outcome collected by telephone.
- TB-500 and KPV — nothing published in humans, for any indication.
That table is the whole human record. Everything else attributed to KLOW is a rodent study, a mechanism, or a photograph. The KLOW complete guide covers what is in the vial.
The BPC-157 number, and what it is
Almost every recovery claim on a KLOW page traces to one 2021 retrospective chart review. A single Florida clinic looked back at 17 patients given BPC-157 injections into the knee. 16 were reachable by phone at six to twelve months. 14 said they felt better.
No control arm, no validated outcome measure, no imaging, and the clinic surveyed its own patients. The placebo response in knee studies runs 30–60%, which is the band that result has to be read against.
Despite the robust preclinical findings, human data are extremely limited, no large-scale randomized trials exist, and BPC-157 should be considered investigational pending well-designed clinical trials.
McGuire et al., Current Reviews in Musculoskeletal Medicine, 2025We work through the design in the knee case series, and the same borrowing problem applies to the three-compound blend in GLOW before and after.
KPV is the newest ingredient and the emptiest record
KPV is the one thing KLOW has that GLOW does not. Its evidence is narrow, clean, and entirely preclinical.
KPV showed significant anti-inflammatory effects in 2 murine models of colitis.
Kannengiesser et al., Inflammatory Bowel Diseases, 2008Two 2008 papers, both mice, one showing PepT1-mediated uptake at nanomolar concentrations in culture. Nothing has followed in humans, for colitis or anything else. So the ingredient that distinguishes KLOW contributes exactly nothing to a before-and-after. See the KPV colitis research.
Why a four-compound photo tells you even less
A before-and-after is an attribution claim: this changed because of that. A blend of four makes the claim unresolvable by construction.
- Four simultaneous variables. If something changed, four things changed, plus whatever else the person changed alongside it.
- The ratio is fixed. Nothing can be varied to test which ingredient matters, because they are in one cake.
- The blue is copper, not a result. GHK-Cu is 62.5% of the mass, and copper(II) is blue in solution.
- Most photos are skin. Those borrow GHK-Cu’s topical evidence for an injected vial — see injectable vs topical.
The copper load is worth its own look for anyone reading results pages as a reason to run a vial faster: about 7.9 mg of elemental copper against a 10 mg adult daily upper intake level. See KLOW side effects and KLOW dosage.
What a real before-and-after looks like
For calibration, a peptide with a genuine measured result is tesamorelin: visceral fat down 15.2% on CT over 26 weeks, against a 5.0% gain on placebo, in 412 randomized adults.
Notice what that has and a KLOW photo does not. A scan. A comparison group. A number that can be wrong. That is the standard, and it is reachable, which is why its absence here is worth naming rather than working around.
What the vial can be checked on is its contents rather than its effects. KLOW benefits traces each claim to its ingredient, and where to buy KLOW covers the four checks a blend certificate has to survive.
What to know now
- No result has been measured for KLOW. Studies of the four-compound combination number zero in any species.
- TB-500 and KPV have no published human trial, so half the vial contributes nothing to any before-and-after.
- The BPC-157 number everyone quotes is a phone survey: 16 knee patients reached, 14 reporting relief, no controls.
- Skin photos borrow GHK-Cu's topical evidence for an injected vial. Injected GHK-Cu has no randomized trial.
- With four fixed-ratio variables, no observed change can be attributed to any one ingredient.
What we're watching
The first thing that would put a real number on this page is the obvious unrun experiment: the blend against each constituent alone, one endpoint, one species. Second would be the first human KPV trial, which would move the newest ingredient from mechanism to outcome. Third, and most consequential by mass, a randomized trial of injected GHK-Cu. Until one of those lands, every KLOW before-and-after is a photograph of a person who changed four things at once.
Frequently asked questions
Are there real KLOW peptide before and after results?
Not measured ones. No study has administered the four compounds together in any species, so there is no published result for the blend. The images in circulation are personal photographs with no baseline, no control and no record of what else changed.
How long does KLOW take to work?
No study defines a timeline, because no study has given the blend. Two of its four ingredients have no published human dose to reconstruct one from.
What is the strongest human evidence behind KLOW?
A 2021 retrospective chart review of 17 knee patients given BPC-157, not KLOW. Sixteen were reached by phone at six to twelve months and fourteen reported relief. There was no control arm and no validated outcome measure.
Does KPV have any human results?
No. KPV's record is two 2008 papers in murine colitis models, one showing uptake through the PepT1 transporter at nanomolar concentrations in culture. No human trial has been published.
Does the blue color mean it is working?
No. The blue is copper(II) from GHK-Cu, which is 62.5% of the vial by mass. It confirms copper is present and says nothing about purity, ratio or effect.
What people actually report
These are self-reports, not evidence. No control group, no blinding, and no independent check that the vial held what the label claimed. They are collected here because people asking about KLOW deserve an answer rather than a refusal, and because what the community believes is itself worth knowing. Quotes are excerpts; each links to the original post.
Self-reports split along one line. Skin and joint changes get reported often, usually between weeks three and six. Hair is the inconsistent one. The biggest KLOW before-and-after on Reddit is a hair post, but the same threads carry people who say their hair did not change at all. Null reports recur in every thread, including one at 60 days and two vials. Commenters in the r/tressless thread describe an early breakout phase they call "copper uglies." None of this is controlled. Nobody is blinded, nobody measures, and most people run KLOW alongside other compounds.
Where the community and the published record disagree. The community's own headline evidence does not exist. The most-upvoted KLOW before-and-after on Reddit, at 831 upvotes, credits "a 5 year study on ipamorelin showing 15% hair density increase at year one and 25% by year five" (verified verbatim in the post). PubMed returns zero results for ipamorelin and hair, though ipamorelin alone returns 54 records. The wider gap has the same shape. PubMed has no study of the four-peptide KLOW combination at all. And it has no human trial of injected GHK-Cu: of 180 GHK-Cu records, the only two human trials are topical cream, a 2006 trial on CO2 laser-resurfaced skin and a 1992 trial of a 0.4% cream on venous stasis ulcers. The rest of the skin work people cite is cell culture and animal models. A 2026 review of injectable peptide therapy says these findings are "largely unvalidated in human trials." So the community argues about ratios and cycling for a formulation the literature has never tested once.
“Ankle and knee pain disappeared by week 1. • My skin is thicker and I noticed slight tightening but nothing major.”
“I'm 60 days and 2 vials in and I get nothing from it. I pulled my groin 3 weeks ago I don't even know how but no healing benefits with that.. no skin benefits literally nothing from it and I'm getting sick of injecting every day..”
“around week 6-8 i noticed my hair was actually thicker. not just "i think it looks better" thick, like visibly filling in on the crown.”
GH peptides + KLOW blend saved my hair. before and after pics.
“I had better results with every one separately than using a blend (and you can control dosage of each) but it's way too much burden to do that many pins”
KLOW injections vs individually dosing GHK-CU, KPV, BPC 157 and TB 500
“Around day 3 I noticed I started to have brain fog I couldn't concentrate on nothing. Then having horrible anxiety, along with head pressure.”
“why some people flare up before they feel better, and why peptides should never replace fixing the actual mechanical triggers behind pain and injury”
Posts are quoted under fair use and linked to their authors. Nothing on this page is hosted here, and no claim above has been verified beyond confirming that the person wrote it.
References
- Lee, E., & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8–13. PMID 34324435
- Vasireddi, N., Hahamyan, H., Salata, M. J., et al. (2025). Emerging use of BPC-157 in orthopaedic sports medicine: A systematic review. HSS Journal, 21(4). https://doi.org/10.1177/15563316251355551
- McGuire, F. P., Martinez, R., Lenz, A., Skinner, L., & Cushman, D. M. (2025). Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine, 18(12), 611–619. https://doi.org/10.1007/s12178-025-09990-7
- Kannengiesser, K., Maaser, C., Heidemann, J., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflammatory Bowel Diseases, 14(3), 324–331. https://doi.org/10.1002/ibd.20334
- Dalmasso, G., Charrier-Hisamuddin, L., Nguyen, H. T., et al. (2008). PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology, 134(1), 166–178. https://doi.org/10.1053/j.gastro.2007.10.026
- Sun, J., Xue, P., Liu, J., et al. (2021). Self-Cross-Linked Hydrogel of Cysteamine-Grafted γ-Polyglutamic Acid Stabilized Tripeptide KPV for Alleviating TNBS-Induced Ulcerative Colitis in Rats. ACS Biomaterials Science & Engineering, 7(10), 4859–4869. https://doi.org/10.1021/acsbiomaterials.1c00792
- Dou, Y., Lee, A., Zhu, L., et al. (2020). The potential of GHK as an anti-aging peptide. Aging Pathobiology and Therapeutics, 2(1), 58–61. https://doi.org/10.31491/apt.2020.03.014
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 19(7), 1987. https://doi.org/10.3390/ijms19071987
- Dymek, M., Warszyński, P., & Sikora, E. (2023). GHK Peptide Permeability and Its Effects in Anti-Aging Skincare Topical Formulations. Pharmaceutics, 15(10), 2485. https://doi.org/10.3390/pharmaceutics15102485
- Ying, Y., Lin, C., Tao, N., et al. (2023). Thymosin β4 and actin: Binding modes, biological functions and clinical applications. Current Protein and Peptide Science, 24(1), 78–88. https://doi.org/10.2174/1389203724666221201093500
- Xing, Y., Ye, Y., Zuo, H., & Li, Y. (2021). Progress on the Function and Application of Thymosin β4. Frontiers in Endocrinology, 12, 767785. https://doi.org/10.3389/fendo.2021.767785